All data are based on the daily closing price as of September 6, 2024
k
Kaken Pharmaceutical
4521.TSE
28.46 USD
0.19
+0.67%
Overview
Last close
28.46 usd
Market cap
1.08B usd
52 week high
28.54 usd
52 week low
20.71 usd
Target price
25.3 usd
Valuation
P/E
21.1416
Forward P/E
N/A
Price/Sales
2.1326
Price/Book Value
1.0703
Enterprise Value
649.40M usd
EV/Revenue
1.2806
EV/EBITDA
10.5783
Key financials
Revenue TTM
507.12M usd
Gross Profit TTM
292.23M usd
EBITDA TTM
82.73M usd
Earnings per Share
1.35 usd
Dividend
1.05 usd
Total assets
1.09B usd
Net debt
-298.61M usd
About
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001 that is in phase II clinical trial for the treatment of refractory vascular malformations; BBI-4000 that is in phase I clinical trial for primary palmoplantar hyperhidrosis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; Seladelpar that is in phase I clinical trial for primary biliary cholangitis; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.